AbbVie ABBV-295 Phase 1 Data Show Long-Acting Potential for Obesity Treatment at EASD 2026
AbbVie has presented detailed Phase 1 data for ABBV-295 at EASD 2026, demonstrating meaningful body weight reduction, favorable tolerability and an approximately 11–12-day half-life. The investigational long-acting amylin analog is advancing toward Phase 2 development for chronic weight management, with potential dosing intervals extending beyond weekly administration.
